Phase 4
Completed N=421
Pain Increases After Shoulder Injection
Source: ClinicalTrials.gov NCT05438277 ↗Enrolled (actual)
421
Serious AEs
—
Results posted
Mar 2023
Primary outcomePrimary: Incidence of a Flare Reaction — 44; 8; 149; 191 Person-visits
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
Compare FLARE reactions (increase in VAS by two or more points) in the first 48 hours following a shoulder injection.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of a Flare Reaction |
44; 8; 149; 191; 16; 28 | — |
Eligibility Criteria
Inclusion Criteria
- Subacromial or glenohumeral shoulder pain to be treated with steroid injection
- Fluent in written and oral English
- Willing and able to provide written consent
- Willing to complete follow up pain scores (visual analog score)
Exclusion Criteria
- Unable to provide written consent
- Chronic pain syndrome
- Unwilling to complete follow up pain scores (visual analog score)
Data sourced from ClinicalTrials.gov (NCT05438277). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.